

REMARKS/ARGUMENTS

Claims 1, 2, 4-11, 21-23, and 26-29 are active. Please enter the Amendment filed April 24, 2008 as well as this Supplemental Amendment. This Supplemental Amendment further limits independent claim 1 and presents clean copies of the remaining claims. The changes to the peptide sequence of claim 1 find support in the specification as follows: Z<sup>7</sup> = Asp (page 11, lines 13-14), J<sup>14</sup> = Ala (page 10, lines 31-32), J<sup>38</sup> = Gln (page 11, line 2), J<sup>62</sup> = Gly (page 11, line 2), and J<sup>75</sup> = Ser (page 11, line 2). New SEQ ID NO: 18 has been added to refer to this sequence. No other substantive amendments have been made and no new matter has been introduced.

The Applicants reiterate the arguments made in the previous response.

Sequence Listing Statement

As required by 37 C.F.R. 1.821(f), the sequence information recorded in the computer-readable form (CRF) of the substitute Sequence Listing is identical to that in the paper copy of the substitute Sequence Listing; or if this substitute Sequence Listing is electronically-filed, then the sequences in the electronically filed Sequence Listing are identical to the sequences disclosed in this application.

Pursuant to 37 C.F.R. 1.821(g) the Applicants state that no new matter has been introduced.

Conclusion

In view of the amendments above, the Applicants respectfully submit that this application is now in condition for allowance. An early notice to that effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

  
Thomas M. Cunningham

Registration No. 45,394

Customer Number  
**22850**

Tel: (703) 413-3000  
Fax: (703) 413 -2220  
(OSMMN 08/07)